摘要
近年来,新型抗类风湿关节炎药不断涌现,包括生物类改善病情抗风湿药(bDMARDs)和靶向合成改善病情抗风湿药(tsDMARDs)。其中,tsDMARDs因其良好的临床疗效、口服制剂的便利性及可控的不良反应而在临床广泛应用。本文就tsDMARDs的作用机制、临床研究、不良反应、上市情况等进行综述,以期为临床应用提供参考。
In recent years,numerous novel drugs for rheumatoid arthritis have been developed,including biological disease-modifying anti-rheumatic drugs(bDMARDs)and targeted synthetic disease-modifying anti-rheumatic drugs(tsDMARDs).Among them,tsDMARDs are widely used in clinic practice due to their favorable clinical efficacy,oral administration convenience and managable adverse reactions.This paper reviews the mechanism of action,clinical study,adverse reactions and listing status of tsDMARDs,in order to provide reference for clinical application.
作者
张淼淼
李婷
张田
王洋
金鹏飞
张亚同
ZHANG Miao-miao;LI Ting;ZHANG Tian;WANG Yang;JIN Peng-fei;ZHANG Ya-tong(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China)
出处
《中国合理用药探索》
CAS
2024年第1期19-24,共6页
Chinese Journal of Rational Drug Use
关键词
类风湿关节炎
靶向合成改善病情抗风湿药
临床研究
作用机制
药品不良反应
rheumatoid arthritis
targeted synthetic disease-modifying anti-rheumatic drugs
clinical study
mechanism of action
adverse drug reaction
